Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/MRNA/Catalyst
Phase 1/2Data readout

mRNA-2808

Multiple Myeloma

MRNAModerna
Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset
mRNA-2808
Development stage
Phase 1/2
Event type
Data readout
Indication
Multiple Myeloma

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for mRNA-2808 in Multiple Myeloma. The expected timing is based on the latest available company guidance and may change.

Development notes

11/3/25- First patient dosed. 11/06/25:- PR No update. 04/21/26:- Ph1/2 mRNA-2808 R/R multiple myeloma study poster at ASCO 2026 on June 1.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from MRNA

Related pipeline programs

Phase 3

mRNA-1403

Norovirus vaccine

View company pipeline
Phase 3

mRNA-4157/V940 +KEYTRUDA

Cancer, Non-small cell lung carcinoma

View company pipeline
Phase 1

mRNA-1574

Human immunodeficiency virus

View company pipeline

Company

Moderna

MRNA · NasdaqGS
Industry
Biotechnology
Pipeline assets
23
View MRNA research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy